{"id":"https://openalex.org/W2767130235","doi":"https://doi.org/10.1080/17474086.2017.1397510","title":"Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia","display_name":"Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia","publication_year":2017,"publication_date":"2017-10-26","ids":{"openalex":"https://openalex.org/W2767130235","doi":"https://doi.org/10.1080/17474086.2017.1397510","mag":"2767130235","pmid":"https://pubmed.ncbi.nlm.nih.gov/29069942"},"language":"en","primary_location":{"id":"doi:10.1080/17474086.2017.1397510","doi":"https://doi.org/10.1080/17474086.2017.1397510","is_oa":true,"landing_page_url":"https://doi.org/10.1080/17474086.2017.1397510","pdf_url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf","source":{"id":"https://openalex.org/S73682863","display_name":"Expert Review of Hematology","issn_l":"1747-4086","issn":["1747-4086","1747-4094"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Review of Hematology","raw_type":"journal-article"},"volume":null,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5023296232","display_name":"Marlise Rachael Luskin","orcid":"https://orcid.org/0000-0002-5781-4529","observed_orcids":["https://orcid.org/0000-0002-5781-4529"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Marlise R. Luskin","raw_affiliation_strings":[",","Harvard Medical School, Boston, MA, USA","Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":",","institution_ids":[]},{"raw_affiliation_string":"Harvard Medical School, Boston, MA, USA","institution_ids":["https://openalex.org/I136199984"]},{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5082924494","display_name":"Daniel J. DeAngelo","orcid":"https://orcid.org/0000-0001-7865-2306","observed_orcids":["https://orcid.org/0000-0001-7865-2306"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel J. DeAngelo","raw_affiliation_strings":[",","Harvard Medical School, Boston, MA, USA","Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":",","institution_ids":[]},{"raw_affiliation_string":"Harvard Medical School, Boston, MA, USA","institution_ids":["https://openalex.org/I136199984"]},{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5023296232"],"corresponding_institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"],"apc_list":null,"apc_paid":null,"fwci":0.3724,"has_fulltext":true,"cited_by_count":21,"citation_normalized_percentile":{"value":0.34430138,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"10","issue":"12","first_page":"1033","last_page":"1045"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/midostaurin","display_name":"midostaurin","score":1.0},{"id":"https://openalex.org/keywords/flt3-itd-mutation","display_name":"FLT3-ITD","score":0.8149999976158142},{"id":"https://openalex.org/keywords/flt3-tkd-mutation","display_name":"FLT3-TKD mutation","score":0.9860000014305115},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9810000061988831},{"id":"https://openalex.org/keywords/flt3-inhibitors","display_name":"FLT3 inhibitors","score":0.7760000228881836},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.8450000286102295},{"id":"https://openalex.org/keywords/multikinase-inhibitor","display_name":"multikinase inhibitor","score":0.8109999895095825},{"id":"https://openalex.org/keywords/newly-diagnosed-aml","display_name":"newly diagnosed AML","score":0.7850000262260437},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.6100000143051147},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.42800000309944153},{"id":"https://openalex.org/keywords/hypomethylating-agents","display_name":"hypomethylating agents","score":0.8650000095367432},{"id":"https://openalex.org/keywords/maintenance-therapy","display_name":"maintenance therapy","score":0.9559999704360962},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.6039999723434448},{"id":"https://openalex.org/keywords/drug-metabolism","display_name":"drug metabolism","score":0.38600000739097595}],"concepts":[{"id":"https://openalex.org/C2776481607","wikidata":"https://www.wikidata.org/wiki/Q6842945","display_name":"Midostaurin","level":3,"score":0.9929267168045044},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8302905559539795},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.6053348183631897},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4796622097492218},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.43010786175727844},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3846457600593567}],"mesh":[{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D002471","descriptor_name":"Cell Transformation, Neoplastic","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009154","descriptor_name":"Mutation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D011379","descriptor_name":"Prognosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015470","descriptor_name":"Leukemia, Myeloid, Acute","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D015470","descriptor_name":"Leukemia, Myeloid, Acute","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015470","descriptor_name":"Leukemia, Myeloid, Acute","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D015470","descriptor_name":"Leukemia, Myeloid, Acute","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017277","descriptor_name":"Drug Approval","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019008","descriptor_name":"Drug Resistance, Neoplasm","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D019311","descriptor_name":"Staurosporine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D019311","descriptor_name":"Staurosporine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D019311","descriptor_name":"Staurosporine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D051941","descriptor_name":"fms-Like Tyrosine Kinase 3","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D051941","descriptor_name":"fms-Like Tyrosine Kinase 3","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D058990","descriptor_name":"Molecular Targeted Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1080/17474086.2017.1397510","doi":"https://doi.org/10.1080/17474086.2017.1397510","is_oa":true,"landing_page_url":"https://doi.org/10.1080/17474086.2017.1397510","pdf_url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf","source":{"id":"https://openalex.org/S73682863","display_name":"Expert Review of Hematology","issn_l":"1747-4086","issn":["1747-4086","1747-4094"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Review of Hematology","raw_type":"journal-article"},{"id":"pmid:29069942","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/29069942","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert review of hematology","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1080/17474086.2017.1397510","doi":"https://doi.org/10.1080/17474086.2017.1397510","is_oa":true,"landing_page_url":"https://doi.org/10.1080/17474086.2017.1397510","pdf_url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf","source":{"id":"https://openalex.org/S73682863","display_name":"Expert Review of Hematology","issn_l":"1747-4086","issn":["1747-4086","1747-4094"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Review of Hematology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9537000060081482,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2767130235.pdf","grobid_xml":"https://content.openalex.org/works/W2767130235.grobid-xml"},"referenced_works_count":87,"referenced_works":["https://openalex.org/W105054394","https://openalex.org/W1255676896","https://openalex.org/W1255933066","https://openalex.org/W1481564836","https://openalex.org/W1521952791","https://openalex.org/W1548583460","https://openalex.org/W1600365609","https://openalex.org/W1744167954","https://openalex.org/W1946364510","https://openalex.org/W1974630669","https://openalex.org/W1974674483","https://openalex.org/W1983999811","https://openalex.org/W1984215832","https://openalex.org/W1984712646","https://openalex.org/W1988047797","https://openalex.org/W1988062934","https://openalex.org/W1990870968","https://openalex.org/W1993300766","https://openalex.org/W1993536389","https://openalex.org/W1996383959","https://openalex.org/W2002927399","https://openalex.org/W2011187792","https://openalex.org/W2015507761","https://openalex.org/W2016883830","https://openalex.org/W2021759592","https://openalex.org/W2041027929","https://openalex.org/W2043216151","https://openalex.org/W2048369203","https://openalex.org/W2050338667","https://openalex.org/W2051531396","https://openalex.org/W2052886921","https://openalex.org/W2057699900","https://openalex.org/W2059150276","https://openalex.org/W2068556430","https://openalex.org/W2069448515","https://openalex.org/W2070308429","https://openalex.org/W2071612423","https://openalex.org/W2073788073","https://openalex.org/W2074425311","https://openalex.org/W2074487662","https://openalex.org/W2078803892","https://openalex.org/W2079025304","https://openalex.org/W2080059445","https://openalex.org/W2084855648","https://openalex.org/W2094520541","https://openalex.org/W2097583774","https://openalex.org/W2103827225","https://openalex.org/W2106084333","https://openalex.org/W2106533048","https://openalex.org/W2109065151","https://openalex.org/W2112414163","https://openalex.org/W2113230030","https://openalex.org/W2114441791","https://openalex.org/W2114942826","https://openalex.org/W2115707319","https://openalex.org/W2125877707","https://openalex.org/W2129615499","https://openalex.org/W2130864403","https://openalex.org/W2132912591","https://openalex.org/W2141034604","https://openalex.org/W2144395887","https://openalex.org/W2147338626","https://openalex.org/W2150470057","https://openalex.org/W2151222524","https://openalex.org/W2153345005","https://openalex.org/W2154625299","https://openalex.org/W2155349260","https://openalex.org/W2199445282","https://openalex.org/W2227512822","https://openalex.org/W2318674152","https://openalex.org/W2330718732","https://openalex.org/W2342077727","https://openalex.org/W2342568086","https://openalex.org/W2415884393","https://openalex.org/W2419140434","https://openalex.org/W2471743272","https://openalex.org/W2472403803","https://openalex.org/W2502940040","https://openalex.org/W2553392785","https://openalex.org/W2559537906","https://openalex.org/W2599431588","https://openalex.org/W2654449699","https://openalex.org/W2715749014","https://openalex.org/W2725930552","https://openalex.org/W2891793888","https://openalex.org/W2979935616","https://openalex.org/W4231346141"],"related_works":["https://openalex.org/W2772795108","https://openalex.org/W2342077727","https://openalex.org/W2768756135","https://openalex.org/W2977354624","https://openalex.org/W2154625299","https://openalex.org/W7028199727","https://openalex.org/W2771914151","https://openalex.org/W2620184199","https://openalex.org/W206224218","https://openalex.org/W3087565861"],"abstract_inverted_index":{"INTRODUCTION:":[0],"Acute":[1],"myeloid":[2],"leukemia":[3],"(AML)":[4],"is":[5,38,46,101,142],"an":[6],"aggressive":[7],"hematologic":[8],"malignancy":[9],"with":[10,40,74,123,172],"inadequate":[11],"treatment":[12,66,79],"options.":[13],"Approximately":[14],"one-third":[15],"of":[16,67,80,88,96,106,114,129,158,168],"cases":[17],"have":[18],"a":[19,41,47,117],"FLT3-ITD":[20,36],"or":[21],"FLT3-TKD":[22],"mutation":[23,37],"which":[24,31],"leads":[25],"to":[26,33,160,194,197],"constitutive":[27],"tyrosine":[28],"kinase":[29],"activation":[30],"contributes":[32],"leukemogenesis.":[34],"The":[35,94,127],"associated":[39],"particularly":[42],"poor":[43],"prognosis.":[44],"Midostaurin":[45,55],"multi-kinase":[48],"inhibitor":[49],"active":[50],"against":[51],"the":[52,59,107,132,144,166],"FLT3":[53,185],"receptor.":[54],"was":[56],"approved":[57,148],"by":[58],"US":[60],"FDA":[61],"in":[62,72,98,121,138,170,189],"April":[63],"2017":[64],"for":[65,136,149],"newly":[68],"diagnosed":[69],"FLT3-mutant":[70,81,99],"AML":[71,82,100,137],"combination":[73,122,171],"chemotherapy.":[75,124],"Areas":[76],"covered:":[77],"Standard":[78],"and":[83,92,111,120,175,183],"outcomes.":[84],"Early":[85],"clinical":[86],"development":[87,95],"midostaurin":[89,97,115,130,161,169],"including":[90,104],"pharmacokinetics":[91],"metabolism.":[93],"then":[102],"outlined":[103],"review":[105],"phase":[108],"I,":[109],"II,":[110],"III":[112],"trials":[113],"as":[116,162,164,176],"single":[118],"agent":[119],"Expert":[125],"commentary:":[126],"approval":[128],"represents":[131],"first":[133,145],"new":[134],"therapy":[135,147],"several":[139],"decades.":[140],"It":[141],"also":[143,188],"targeted":[146],"AML.":[150],"Future":[151],"studies":[152],"will":[153],"focus":[154],"on":[155],"defining":[156],"mechanisms":[157],"resistance":[159],"well":[163],"establishing":[165],"role":[167],"hypomethylating":[173],"agents":[174,192],"maintenance":[177],"therapy.":[178],"Second":[179],"generation,":[180],"more":[181],"potent":[182],"selective":[184],"inhibitors":[186],"are":[187],"development;":[190],"these":[191],"need":[193],"be":[195],"compared":[196],"midostaurin.":[198]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":4},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":3}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2017-11-10T00:00:00"}